Recent news on Olmesartan

Olmesartan Medoxomil and Hydrochlorothiazide Work Better Together ...  -  May 24, 2007
DG NewsThe least squares mean (LSM) differences in mean seated diastolic blood pressure at the end of the trial for olmesartan 20 mg and 40 mg combined with HCTZ

Amlodipine And Olmesartan Study Results Released; Late Breaker ...  -  May 22, 2007
Medical News Today (press release),Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil, produced significant mean reductions

Amlodipine and Olmesartan Study Results Released; Late Breaker ...  -  May 21, 2007
PR Newswire (press release),PARSIPPANY, NJ, May 21 /PRNewswire/ -- Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil,

Amlodipine and Olmesartan Study Results Released; Late Breaker ...  -  May 21, 2007
Market Wire (press release)This investigational agent of amlodipine besylate/olmesartan medoxomil (AZOR™) is under regulatory review in the United States, including trade name review.

ASH: More Proves Better in Treating Hypertension  -  May 23, 2007
MedPage Today,The combination of the calcium channel blocker amlodipine and an angiotensin-receptor blocker -- either valsartan or olmesartan -- resulted in a greater

BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for ...  -  May 21, 2007
PR Newswire (press release),Patients were randomized to either 2 weeks of double-blind titration with olmesartan medoxomil 20 mg and then uptitrated to olmesartan medoxomil 40 mg for 2

Analysis: Combos best for blood pressure?  -  May 22, 2007
United Press InternationalIn two trials, doctors combined amlodipine with the angiotension receptor blockers valsartan or olmesartan and came up with similar conclusions: The

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure ...  -  May 21, 2007
Earthtimes.orgBenicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ...  -  May 23, 2007
PharmaLive.com (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter ...  -  Apr 24, 2007
PR-Inside.com (Pressemitteilung),...earnings contribution of $45870000 from the co-promotion of Benicar(R) (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies,

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal ...  -  Apr 12, 2007
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

DAIICHI SANKYO - Merger for Worldwide Growth Successfully Completed  -  Apr 5, 2007
Drug Newswire (press release),Apart from the strategic expansion of the R&D pipeline, the development of the most important products such as Olmesartan (anti-hypertensive agent) and

Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to ...  -  Mar 29, 2007
Drug Newswire (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing for WelChol Label Change to ...  -  Mar 28, 2007
WM Experts (press release),Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo Announces Completion of Phase I Trial on the Anti ...  -  Apr 19, 2007
PharmaLive.com (press release),Sankyo and Daiichi Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar (olmesartan

Daiichi Sankyo sets challenging sales targets for Europe  -  Apr 3, 2007
Pharma Times (subscription),...co-developed with Eli Lilly, while a combination antihypertensive consisting of the firm's best-selling Benicar/Olmetec (olmesartan) and amlodipine will

New Drugs from Novartis and Daiichi Sankyo Will Achieve ...  -  Mar 22, 2007
Drug Newswire (press release),As a result, Exforge and amlodipine/olmesartan will both achieve blockbuster status by 2015, earning $3.2 billion and $1.9 billion, respectively.

New drug battles 'silent killer'  -  Mar 7, 2007
DrugResearcher.com,Daiichi Sankyo is also taking advantage of Norvasc losing patent protection by combining it with its own hypertension product, Benicar (olmesartan).

Forest Laboratories Announces Rule 144 Sale by Executive Officer  -  Feb 15, 2007
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin

DAIICHI SANKYO returns development rights of KAI-9803  -  Feb 9, 2007
PipelineReview.com (press release),Sankyo and Daiichi Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar® (olmesartan

Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share ...  -  Jan 16, 2007
Drug Newswire (press release),...earnings contribution of $38664000 from the co-promotion of Benicar(R)* (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies,

Forest Laboratories Announces Completion of Acquisition of Cerexa ...  -  Jan 11, 2007
Yahoo! News (press release)Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT® (olmesartan medoxomil- hydrochlorothiazide),

A Rho-kinase inhibitor, fasudil, prevents development of diabetes ...  -  Jan 3, 2007
Journal of EndocrinologyWe assessed these effects of fasudil in insulin-resistant diabetic rats, comparing them with those of an angiotensin II receptor blocker, olmesartan.

Forest Labs Q3 Profit Surges 28% Helped By Namenda, Lexapro Sales ...  -  Jan 16, 2007
Trading Markets,Sales benefited from the contribution of $38.6 million from the co-promotion of Benicar (olmesartan medoxomil) and Benicar HCT antihypertensive therapies,

Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug ...  -  Jan 3, 2007
Medical News Today (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug ...  -  Jan 3, 2007
PipelineReview.com (press release),Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte ...  -  Nov 30, 2006
Japan Corporate News (press release),In a clinical trial, the amlodipine/olmesartan combination demonstrated clinically significant mean blood pressure reductions. It utilizes two complementary

Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus ...  -  Dec 14, 2006
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus ...  -  Dec 14, 2006
Yahoo! News (press release)Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT® (olmesartan medoxomil- hydrochlorothiazide),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional